Payment overview · 2025
General Payments
$3,797.19
172 reported records · 20 companies
Healthcare provider profile · identity verified
Erick Bournigal, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · BRUNSWICK, GA · NPI 1275548547
Verified facts
What the public records show
CMS Open Payments records show Erick Bournigal, MD received $3,797.19 in general payments during 2025 across 172 reported records.
ABBVIE INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Acthar, Horizant, Kevzara, Rinvoq, Tremfya, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Enbrel by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Horizant by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Kevzara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tremfya by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Acthar by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $702.78 | 18.5% | 36 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $623.90 | 16.4% | 29 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $596.73 | 15.7% | 23 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $384.53 | 10.1% | 20 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $305.14 | 8.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $236.77 | 6.2% | 15 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $207.01 | 5.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.06 | 4.5% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $108.04 | 2.9% | 6 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.28 | 2.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $63.57 | 1.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.32 | 1.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.30 | 1.3% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.73 | 1.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $32.79 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.14 | 0.8% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $31.03 | 0.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $28.69 | 0.8% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $23.56 | 0.6% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $18.82 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,698.19 | 171 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $461.29 | 22 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $438.93 | 18 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $424.09 | 24 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $384.53 | 20 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $305.14 | 9 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $236.77 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $232.15 | 9 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $207.01 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $162.88 | 10 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $150.08 | 7 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $108.04 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $88.28 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $63.57 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $53.32 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.30 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $46.54 | 3 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ACTHAR acthar |
2025 | Acthar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 95 | exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 947 | 391 |
| Tizanidine Hcl | Tizanidine Hcl | 552 | 231 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 396 | 123 |
| Prednisone | Prednisone | 346 | 132 |
| Tramadol Hcl | Tramadol Hcl | 315 | 54 |
| Methotrexate | Methotrexate Sodium | 314 | 93 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 250 | 116 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 215 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 59 |
| Allopurinol | Allopurinol | 140 | 48 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 100 | 32 |
| Tymlos | Abaloparatide | 99 | 20 |
| Rinvoq | Upadacitinib | 95 | 14 |
| Trazodone Hcl | Trazodone Hcl | 81 | 20 |
| Levetiracetam | Levetiracetam | 79 | 33 |
| Enbrel Mini | Etanercept | 66 | suppressed |
| Kevzara | Sarilumab | 62 | suppressed |
| Enbrel Sureclick | Etanercept | 60 | suppressed |
| Levetiracetam Er | Levetiracetam | 59 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 22 |
| Lamotrigine | Lamotrigine | 55 | 29 |
| Leflunomide | Leflunomide | 52 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 16 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Meloxicam | Meloxicam | 40 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 13 |
| Zonisamide | Zonisamide | 37 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | 12 |
| Humira(Cf) Pen | Adalimumab | 31 | suppressed |
| Humira(Cf) | Adalimumab | 30 | suppressed |
| Vraylar | Cariprazine Hcl | 30 | 11 |
| Ammonium Lactate | Ammonium Lactate | 28 | 14 |
| Leucovorin Calcium | Leucovorin Calcium | 28 | 11 |
| Aripiprazole | Aripiprazole | 26 | 13 |
| Taltz Autoinjector | Ixekizumab | 25 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 18 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 18 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Acthar | Corticotropin | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 15 | suppressed |
| Enbrel | Etanercept | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Orencia | Abatacept | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Tremfya | Guselkumab | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,797.19 · 172 records | ABBVIE INC. | ACTHAR, Actemra, Auvelity, BENLYSTA, Bimzelx, CAPLYTA, COSENTYX, EVENITY, HADLIMA, HORIZANT, KEVZARA, KRYSTEXXA, LUPKYNIS, PROLIA, PURIFIED CORTROPHIN GEL, RENFLEXIS, REXULTI, RINVOQ, SAPHNELO, SKYRIZI, TREMFYA, Tyenne, UPLIZNA, VRAYLAR, XELJANZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Acthar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error